(Q42460848)

1 November 2017

title

Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells (English)

1 reference

1 November 2017

2

Yusuf Baran

1 reference

1 November 2017

Serdar Goktas

1

1 reference

1 November 2017

Ali U Ural

3

1 reference

1 November 2017

Sertac Yazici

4

1 reference

1 November 2017

Emin Aydur

5

1 reference

1 November 2017

Seref Basal

6

1 reference

1 November 2017

Ferit Avcu

7

1 reference

1 November 2017

Aysel Pekel

8

1 reference

1 November 2017

Bahar Dirican

9

1 reference

1 November 2017

Murat Beyzadeoglu

10

1 reference

1 November 2017

language of work or name

English

0 references

publication date

2 October 2009

1 reference

1 November 2017

1 reference

1 November 2017

volume

75

1 reference

1 November 2017

issue

4

1 reference

1 November 2017

page(s)

793-798

1 reference

1 November 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Contemporary results of anatomic radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Natural history of progression after PSA elevation following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Novel agents and targets in managing patients with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Proteasome inhibition: a new strategy in cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

New insights into proteasome function: from archaebacteria to drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Bortezomib as a potential treatment for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

NF-kappa B as a therapeutic target in multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

The proteasome: structure, function, and role in the cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Molecular pathways that modify tumor radiation response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.07.1215

10.1016/J.UROLOGY.2009.07.1215

7 January 2021

Identifiers

DOI

1 reference

1 November 2017

1 reference